Patients with chronic lymphocytic leukemia (CLL) are known to be at a higher risk of developing other primary cancers (OPC). Identifying latency and risk factors associated with OPCs in CLL is of interest as select patients may potentially benefit from early treatment of CLL with targeted therapies to improve immune surveillance. In this single-center retrospective study, 16.9% of 969 patients with CLL were diagnosed with an OPC. Interestingly, 44% of OPCs were diagnosed prior to the CLL diagnosis, including 30% that were diagnosed >1 year prior. This included a majority of genitourinary cancers and melanoma skin cancers. Patients with CLL and an OPC were older than pts with no OPCs but no other risk factors for developing OPCs were identified. Our data suggest that not only are patients with CLL at higher risk of developing OPCs and warrant appropriate cancer surveillance, but the risk also precedes CLL diagnosis by several years.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/10428194.2021.2012662 | DOI Listing |
Asian Pac J Cancer Prev
January 2025
Principal Scientific Officer & Molecular Advisor, Rajiv Gandhi Cancer Institute & Research Centre, New Delhi, India.
Chronic lymphocytic leukemia (CLL) is a less common hematological malignancy in Indian people. It accounts for less than 5% of all leukemias. Information on genomic alteration in CLL is limited immunoglobulin heavy-chain variable region (IGHV) mutational status is considered the most reliable prognostic marker.
View Article and Find Full Text PDFCancer Med
February 2025
Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Chiba, Japan.
Background: Due to its rarity, there are very limited data available on the cause of death (COD) and its association with comorbidities in Japanese chronic lymphocytic leukemia (CLL) patients.
Methods: To investigate the prevalence of comorbidities and their impact on cause-specific mortality, we retrospectively reviewed 121 Japanese patients with CLL.
Results: The median age was 69 years, with 47.
Am J Hematol
January 2025
Department I of Internal Medicine and Medical Faculty, University of Cologne, Köln, Germany.
Disease Overview: Chronic lymphocytic leukemia (CLL) is the most frequent type of leukemia. It typically occurs in older patients and has a highly variable clinical course. Leukemic transformation is initiated by specific genomic alterations that interfere with the regulation of proliferation and apoptosis in clonal B-cells.
View Article and Find Full Text PDFObjectives: Patients with chronic lymphocytic leukaemia (CLL) have an increased risk of severe coronavirus disease 2019 (COVID-19) as well as impaired responses to COVID-19 vaccination, which may be overcome by repeated booster vaccinations. Our objective was to explore the uptake of the COVID-19 vaccine in this population since records of this are scarce.
Methods: In this nationwide cohort study, we used multiple population-based health and sociodemographic registries to study COVID-19 vaccine uptake in individuals with CLL in Sweden, from 27 December 2020 to 28 February 2023.
Background: Patients with chronic lymphocytic leukemia (CLL) are susceptible to infections that can affect their clinical outcomes.
Aims: To assess: (1) the incidence of pneumonia in CLL patients treated with venetoclax-based regimens in a real-world setting, (2) the risk factors for event-free survival (EFS), and (3) overall survival (OS).
Methods: This multicenter study included 322 patients from eight centers.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!